New strategy for monitoring targeted therapy: molecular imaging

Fei-Fei Teng, Xue Meng, Xin-Dong Sun, Jin-Ming YuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University, Jinan, People's Republic of ChinaAbstract: Targeted therapy is becoming an increasingly important component in the treatment of cancer. How to accur...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Teng FF, Meng X, Sun XD, Yu JM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/67d2287e638543e395096aab7516bc87
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:67d2287e638543e395096aab7516bc87
record_format	dspace
spelling	oai:doaj.org-article:67d2287e638543e395096aab7516bc872021-12-02T02:11:17ZNew strategy for monitoring targeted therapy: molecular imaging1176-91141178-2013https://doaj.org/article/67d2287e638543e395096aab7516bc872013-09-01T00:00:00Zhttp://www.dovepress.com/new-strategy-for-monitoring-targeted-therapy-molecular-imaging-a14527https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Fei-Fei Teng, Xue Meng, Xin-Dong Sun, Jin-Ming YuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University, Jinan, People's Republic of ChinaAbstract: Targeted therapy is becoming an increasingly important component in the treatment of cancer. How to accurately monitor targeted therapy has been crucial in clinical practice. The traditional approach to monitor treatment through imaging has relied on assessing the change of tumor size by refined World Health Organization criteria, or more recently, by the Response Evaluation Criteria in Solid Tumors. However, these criteria, which are based on the change of tumor size, show some limitations for evaluating targeted therapy. Currently, genetic alterations are identified with prognostic as well as predictive potential concerning the use of molecularly targeted drugs. Conversely, considering the limitations of invasiveness and the issue of expression heterogeneity, molecular imaging is better able to assay in vivo biologic processes noninvasively and quantitatively, and has been a particularly attractive tool for monitoring treatment in clinical cancer practice. This review focuses on the applications of different kinds of molecular imaging including positron emission tomography-, magnetic resonance imaging-, ultrasonography-, and computed tomography-based imaging strategies on monitoring targeted therapy. In addition, the key challenges of molecular imaging are addressed to successfully translate these promising techniques in the future.Keywords: molecular imaging, targeted therapy, PET, MRI, US, CTTeng FFMeng XSun XDYu JMDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2013, Iss Issue 1, Pp 3703-3713 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Teng FF Meng X Sun XD Yu JM New strategy for monitoring targeted therapy: molecular imaging
description	Fei-Fei Teng, Xue Meng, Xin-Dong Sun, Jin-Ming YuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University, Jinan, People's Republic of ChinaAbstract: Targeted therapy is becoming an increasingly important component in the treatment of cancer. How to accurately monitor targeted therapy has been crucial in clinical practice. The traditional approach to monitor treatment through imaging has relied on assessing the change of tumor size by refined World Health Organization criteria, or more recently, by the Response Evaluation Criteria in Solid Tumors. However, these criteria, which are based on the change of tumor size, show some limitations for evaluating targeted therapy. Currently, genetic alterations are identified with prognostic as well as predictive potential concerning the use of molecularly targeted drugs. Conversely, considering the limitations of invasiveness and the issue of expression heterogeneity, molecular imaging is better able to assay in vivo biologic processes noninvasively and quantitatively, and has been a particularly attractive tool for monitoring treatment in clinical cancer practice. This review focuses on the applications of different kinds of molecular imaging including positron emission tomography-, magnetic resonance imaging-, ultrasonography-, and computed tomography-based imaging strategies on monitoring targeted therapy. In addition, the key challenges of molecular imaging are addressed to successfully translate these promising techniques in the future.Keywords: molecular imaging, targeted therapy, PET, MRI, US, CT
format	article
author	Teng FF Meng X Sun XD Yu JM
author_facet	Teng FF Meng X Sun XD Yu JM
author_sort	Teng FF
title	New strategy for monitoring targeted therapy: molecular imaging
title_short	New strategy for monitoring targeted therapy: molecular imaging
title_full	New strategy for monitoring targeted therapy: molecular imaging
title_fullStr	New strategy for monitoring targeted therapy: molecular imaging
title_full_unstemmed	New strategy for monitoring targeted therapy: molecular imaging
title_sort	new strategy for monitoring targeted therapy: molecular imaging
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/67d2287e638543e395096aab7516bc87
work_keys_str_mv	AT tengff newstrategyformonitoringtargetedtherapymolecularimaging AT mengx newstrategyformonitoringtargetedtherapymolecularimaging AT sunxd newstrategyformonitoringtargetedtherapymolecularimaging AT yujm newstrategyformonitoringtargetedtherapymolecularimaging
_version_	1718402652814966784

New strategy for monitoring targeted therapy: molecular imaging

Ejemplares similares